UCB, Drug Prices & Medicare Spending
UCB manufactures 5 drugs tracked by Medicare Part D with total spending of $2.5B.
UCB Drugs, Ranked by Medicare Spending
| # | Drug | Generic Name | Cost/Claim | Generic? |
|---|---|---|---|---|
| 1 | Cimzia | Certolizumab Pegol | $3,532.00 | Yes |
| 2 | Vimpat | Lacosamide | $270.00 | Yes |
| 3 | Briviact | Brivaracetam | $399.00 | Yes |
| 4 | Neupro | Rotigotine | $375.00 | Yes |
| 5 | Levetiracetam | Levetiracetam | $21.00 | Yes |
Frequently Asked Questions
UCB manufactures 5 drugs tracked by Medicare Part D, with total annual spending of $2.5B.
Cimzia (Certolizumab Pegol) is the most expensive at $3,532.00 per claim.
5 of 5 UCB drugs (100%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.
For this entity, the underlying data on this page comes from CMS Medicare Part D Drug Spending data. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. prescription drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.
Source: CMS Medicare Part D Spending, 2026.